Entries of Repp, Roland on the publication server

Röllig, Christoph, Serve, Hubert, Noppeney, Richard, Hanoun, Maher, Krug, Utz, Baldus, Claudia D., Brandts, Christian H., Kunzmann, Volker, Einsele, Hermann, Krämer, Alwin, Müller-Tidow, Carsten, Schäfer-Eckart, Kerstin, Neubauer, Andreas, Burchert, Andreas, Giagounidis, Aristoteles, Krause, Stefan W., Mackensen, Andreas, Aulitzky, Walter, Herbst, Regina, Hänel, Mathias, Frickhofen, Norbert, Kullmer, Johannes, Kaiser, Ulrich, Kiani, Alexander, Link, Hartmut, Geer, Thomas, Reichle, Albrecht, Junghanß, Christian, Repp, Roland, Meinhardt, Achim, Dürk, Heinz, Klut, Ina-Maria, Bornhäuser, Martin, Schaich, Markus, Parmentier, Stefani, Görner, Martin, Thiede, Christian, von Bonin, Malte, Platzbecker, Uwe, Schetelig, Johannes, Kramer, Michael, Berdel, Wolfgang E. and Ehninger, Gerhard (2021) Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial. Leukemia 35 (9), pp. 2517-2525. Fulltext not available.

Röllig, Christoph, Serve, Hubert , Hüttmann, Andreas, Noppeney, Richard, Müller-Tidow, Carsten, Krug, Utz, Baldus, Claudia D, Brandts, Christian H , Kunzmann, Volker, Einsele, Hermann, Krämer, Alwin, Schäfer-Eckart, Kerstin, Neubauer, Andreas, Burchert, Andreas, Giagounidis, Aristoteles, Krause, Stefan W , Mackensen, Andreas, Aulitzky, Walter, Herbst, Regina, Hänel, Mathias, Kiani, Alexander, Frickhofen, Norbert, Kullmer, Johannes, Kaiser, Ulrich, Link, Hartmut, Geer, Thomas, Reichle, Albert, Junghanß, Christian, Repp, Roland, Heits, Frank, Dürk, Heinz, Hase, Jana, Klut, Ina-Maria, Illmer, Thomas, Bornhäuser, Martin, Schaich, Markus, Parmentier, Stefani, Görner, Martin, Thiede, Christian , von Bonin, Malte, Schetelig, Johannes, Kramer, Michael, Berdel, Wolfgang E and Ehninger, Gerhard (2015) Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. The Lancet Oncology 16 (16), pp. 1691-1699. Fulltext not available.